Surgical excision is the most common treatment for basal cell carcinoma (BCC). A surgeon removes the tumor along with a margin of healthy-looking skin around it, then sends the tissue to a lab to confirm the edges are cancer-free. But the best treatment for any individual BCC depends on its size, location, and how aggressive it looks under a microscope. Low-risk tumors on the trunk might need nothing more than a quick in-office scraping, while high-risk tumors on the face often call for a more precise surgical technique.
How Risk Level Shapes Treatment
Not all basal cell carcinomas behave the same way. Doctors classify each tumor as low-risk or high-risk based on a few key features: where it is on the body, how large it is, and what subtype it is under the microscope. High-risk zones include the central face, nose, eyelids, ears, and genitalia. Medium-risk areas include the cheeks, forehead, scalp, and neck. The trunk and most of the limbs are considered low-risk locations.
A small, well-defined BCC on your back is a very different clinical problem than an aggressive subtype growing near your eye. That distinction drives every treatment decision that follows.
Standard Surgical Excision
For the majority of basal cell carcinomas, standard excision is the go-to treatment. The surgeon uses a scalpel to cut out the visible tumor plus a buffer of surrounding tissue. For low-risk, well-defined tumors smaller than 2 cm, a 4-mm margin of normal skin results in complete removal in more than 95% of cases. High-risk tumors require wider margins, often 4 to 6 mm or more, though guidelines stop short of recommending a single fixed margin because high-risk tumors vary so much in their characteristics.
The removed tissue is examined under a microscope. If cancer cells are found at the edges, a second procedure may be needed. Most excision wounds are closed with stitches the same day, and full scar maturation can take up to a year, with the scar gradually flattening and fading over that time.
Mohs Surgery for High-Risk Tumors
Mohs micrographic surgery is a specialized technique where the surgeon removes thin layers of tissue one at a time, examining each layer under a microscope before deciding whether to take more. This process continues until no cancer cells remain at the margins. It’s the most precise option available, and it spares the maximum amount of healthy tissue.
Mohs is typically recommended for BCCs in cosmetically or functionally sensitive areas (around the eyes, nose, lips, and ears), for large or aggressive subtypes, and for tumors that have come back after previous treatment. A study of facial BCCs found that 5-year recurrence rates after Mohs surgery ranged from about 2.4% for recurrent tumors to 3.4% for primary tumors. Those numbers are consistently lower than recurrence rates with standard excision alone, which is why Mohs is preferred when the stakes of recurrence are highest.
The procedure is done in an outpatient setting, usually under local anesthesia. It can take several hours because of the wait between tissue layers, but you go home the same day.
Curettage and Electrodesiccation
For small, superficial BCCs in low-risk areas, curettage and electrodesiccation (often called “scrape and burn”) is a common and effective choice. The doctor scrapes the tumor away with a sharp, spoon-shaped instrument, then uses an electric needle to destroy any remaining cancer cells and stop bleeding. This cycle is typically repeated two or three times in the same session.
Clearance rates for superficial BCC treated with curettage alone reach about 96% at one year, and adding electrodesiccation improves those numbers further. Wound healing takes roughly four weeks. This method is not appropriate for tumors on the face, for aggressive subtypes, or for larger lesions, because it doesn’t allow the removed tissue to be checked under a microscope.
Radiation Therapy
Radiation is reserved for patients who can’t undergo surgery or prefer a nonsurgical approach, particularly for tumors in cosmetically sensitive areas. It works by directing focused energy at the tumor over a series of sessions, typically spanning about 7 to 8 weeks.
Newer image-guided radiation techniques have shown strong results. In a large analysis of nearly 10,000 BCC lesions, the 2-year freedom from recurrence rate was 99.6%, and that held steady at 99.5% even at 6 years. Radiation doesn’t leave a surgical scar, but it can cause skin changes in the treated area over time, and it’s generally not repeated in the same spot if the cancer returns.
Topical Treatments for Superficial BCC
Two prescription creams can treat superficial basal cell carcinoma: one that activates the immune system to attack cancer cells (imiquimod) and one that directly kills rapidly dividing cells (fluorouracil). Imiquimod has reported clearance rates ranging from 43% to 100% for superficial BCC, depending on the study. Fluorouracil achieves roughly 90% clearance for the same tumor type.
These topical options are best suited for patients with small tumors in low-risk body locations who can’t or won’t undergo surgery. The creams are applied at home over several weeks, but they cause significant skin irritation, redness, and crusting in the treatment area. Because long-term recurrence data is limited compared to surgery, close follow-up is essential for anyone treated this way.
Targeted Therapy for Advanced Cases
In rare cases, basal cell carcinoma grows too large for surgery or spreads to other parts of the body. For these advanced tumors, oral medications that block a specific growth signal called the Hedgehog pathway can shrink or stabilize the cancer. The first drug in this class was approved in 2012 for locally advanced BCC that has recurred after surgery, metastatic BCC, and cases where neither surgery nor radiation is feasible.
These medications work, but they come with notable side effects. In clinical trials, muscle spasms affected 72% of patients, hair loss occurred in 64%, taste changes in 55%, fatigue in 40%, and weight loss in 45%. Because of this side effect burden, Hedgehog pathway inhibitors are not used for typical BCC cases and are reserved for tumors that have exhausted other options.
What Recovery Looks Like
Recovery after BCC surgery varies with the procedure. Curettage wounds heal in about four weeks and are left to close on their own. Excision and Mohs wounds are usually stitched closed, with sutures removed at a follow-up visit within one to two weeks. Your doctor will give you specific timelines for when you can exercise, shower normally, and wear makeup over the site.
Regardless of the treatment method, the surgical site continues to remodel for months. Scars flatten and fade significantly over the course of a year. After any BCC treatment, regular skin checks are important because having one basal cell carcinoma increases your risk of developing another in a different location.